This study presents the first evidence that the cellular specificity of DW-MRS could be exploited for monitoring the effect of tau accumulation on neurons, paving the way to a potential use of DW-MRS for tracking the effect of disease-modifying therapies targeting tau in Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.